fluconazole has been researched along with Vaginosis, Bacterial in 11 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Vaginosis, Bacterial: Polymicrobial, nonspecific vaginitis associated with positive cultures of Gardnerella vaginalis and other anaerobic organisms and a decrease in lactobacilli. It remains unclear whether the initial pathogenic event is caused by the growth of anaerobes or a primary decrease in lactobacilli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary end points were bacterial vaginosis (BV), vaginal candidiasis, trichomoniasis vaginalis (hereafter, "trichomoniasis"), and colonization with Lactobacillus organisms." | 2.73 | Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. ( Baeten, JM; Chohan, V; Hassan, WM; Holmes, KK; Jaoko, W; Kiarie, J; Kurth, AE; Lavreys, L; Mandaliya, K; McClelland, RS; Ndinya-Achola, JO; Richardson, BA, 2008) |
| "Vulvovaginal candidiasis is estimated to be the second most common cause of vaginitis after bacterial vaginosis." | 2.46 | Candidiasis (vulvovaginal). ( Spence, D, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palma, E | 1 |
| Recine, N | 1 |
| Domenici, L | 1 |
| Giorgini, M | 1 |
| Pierangeli, A | 1 |
| Panici, PB | 1 |
| Mochache, V | 1 |
| McClelland, RS | 3 |
| Balkus, JE | 2 |
| Kaur, R | 1 |
| Garg, T | 1 |
| Goyal, AK | 1 |
| Rath, G | 1 |
| Pendharkar, S | 1 |
| Brandsborg, E | 1 |
| Hammarström, L | 1 |
| Marcotte, H | 1 |
| Larsson, PG | 1 |
| Donders, G | 1 |
| Bellen, G | 1 |
| Ausma, J | 1 |
| Verguts, L | 1 |
| Vaneldere, J | 1 |
| Hinoul, P | 1 |
| Borgers, M | 1 |
| Janssens, D | 1 |
| Spence, D | 1 |
| Jaoko, W | 2 |
| Mandaliya, K | 2 |
| Richardson, BA | 2 |
| Masese, L | 1 |
| Gitau, R | 1 |
| Kiarie, J | 2 |
| Marrazzo, J | 1 |
| Farquhar, C | 1 |
| Ressel, GW | 1 |
| Buscemi, L | 1 |
| Arechavala, A | 1 |
| Negroni, R | 1 |
| Villagrana-Zesati, R | 1 |
| Reyna-Figueroa, J | 1 |
| Ortiz-Ibarra, J | 1 |
| Hassan, WM | 1 |
| Chohan, V | 1 |
| Lavreys, L | 1 |
| Ndinya-Achola, JO | 1 |
| Baeten, JM | 1 |
| Kurth, AE | 1 |
| Holmes, KK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Lactobacilli Implementation to Restore a Balanced Vaginal Ecosystem: a Promising Solution Against Vaginosis, Vaginitis and HPV Infection[NCT03372395] | Phase 2 | 117 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Probiotics Role in HPV Clearance When Coexisting Vaginal Infections[NCT05109533] | 483 participants (Actual) | Interventional | 2018-01-01 | Completed | |||
| Vaginal Colonization After Treatment With Lactobacillus in Women With BV or Candida Will That Increase the Cure Rate After Treatment With Clindamycin for BV and Flucnazole for Candida[NCT02295579] | 50 participants (Actual) | Observational [Patient Registry] | 2014-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fluconazole and Vaginosis, Bacterial
| Article | Year |
|---|---|
Candidiasis (vulvovaginal).
Topics: Acute Disease; Administration, Oral; Candida albicans; Candidiasis, Vulvovaginal; Evidence-Based Med | 2010 |
5 trials available for fluconazole and Vaginosis, Bacterial
| Article | Year |
|---|---|
Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV-infection.
Topics: Administration, Intravaginal; Adult; Female; Fluconazole; Humans; Lacticaseibacillus rhamnosus; Metr | 2018 |
Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV-infection.
Topics: Administration, Intravaginal; Adult; Female; Fluconazole; Humans; Lacticaseibacillus rhamnosus; Metr | 2018 |
Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV-infection.
Topics: Administration, Intravaginal; Adult; Female; Fluconazole; Humans; Lacticaseibacillus rhamnosus; Metr | 2018 |
Long-term Lactobacillus rhamnosus BMX 54 application to restore a balanced vaginal ecosystem: a promising solution against HPV-infection.
Topics: Administration, Intravaginal; Adult; Female; Fluconazole; Humans; Lacticaseibacillus rhamnosus; Metr | 2018 |
Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection.
Topics: Administration, Intravaginal; Adult; Anti-Bacterial Agents; Antifungal Agents; Candidiasis, Vulvovag | 2015 |
The posttrial effect of oral periodic presumptive treatment for vaginal infections on the incidence of bacterial vaginosis and Lactobacillus colonization.
Topics: Adolescent; Adult; Anti-Infective Agents; Antifungal Agents; Cohort Studies; Female; Fluconazole; Fo | 2012 |
Short-term therapy for mixed vaginal infections.
Topics: Administration, Oral; Antifungal Agents; Antiprotozoal Agents; Antitrichomonal Agents; Candidiasis, | 2006 |
Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial.
Topics: Adolescent; Adult; Anti-Infective Agents; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluc | 2008 |
5 other studies available for fluconazole and Vaginosis, Bacterial
| Article | Year |
|---|---|
Periodic presumptive treatment for women with prevalent vaginal infections: secondary analysis of data from a randomized controlled trial.
Topics: Adult; Anti-Infective Agents; Candidiasis, Vulvovaginal; Chemoprevention; Female; Fluconazole; Human | 2014 |
Development, Optimization and Evaluation of Electrospun Nanofibers: Tool for Targeted Vaginal Delivery of Antimicrobials Against Urinary Tract Infections.
Topics: Adhesiveness; Administration, Intravaginal; Animals; Anti-Bacterial Agents; Calorimetry, Differentia | 2016 |
The effect of antifungal treatment on the vaginal flora of women with vulvo-vaginal yeast infection with or without bacterial vaginosis.
Topics: Administration, Oral; Antifungal Agents; Bacteria; Candidiasis, Vulvovaginal; Female; Fluconazole; H | 2011 |
CDC releases 2002 guidelines for treating STDs: Part I. Diseases characterized by vaginal discharge and PID.
Topics: Anti-Infective Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Metronidazole; Pelvic | 2002 |
[Study of acute vulvovaginitis in sexually active adult women, with special reference to candidosis, in patients of the Francisco J. Muñiz Infectious Diseases Hospital].
Topics: Acute Disease; Adolescent; Adult; Argentina; Candida; Candidiasis, Vulvovaginal; Carrier State; Como | 2004 |